OTC:INIS
INTERNATIONAL ISOTOPES INC
A niche OTC stock providing critical short-lived isotopes for nuclear medicine imaging and therapy to a growing global market.
Key Metrics
Investment Thesis
Bull Case
International Isotopes offers exposure to the rapidly expanding nuclear medicine market with a unique product portfolio that faces high barriers to entry. The company's revenue growth trajectory and positive operating cash flow suggest operational improvements despite current thin margins. Investors may view this as a turnaround opportunity given its critical role in modern cancer diagnostics.
Bear Case
The stock carries substantial risk due to a massive retained earnings deficit of $127.3M and negligible net profit over the last three years. High operating expenses relative to revenue indicate ongoing efficiency challenges that could delay profitability for an extended period. As an OTC small-cap, liquidity constraints and limited analyst coverage add significant uncertainty to valuation.
About INTERNATIONAL ISOTOPES INC
International Isotopes Inc. is a leading provider of high-specific activity isotopes and radiopharmaceuticals used in nuclear medicine imaging and therapy. The company serves global markets including the United States, Europe, and Asia with products essential for cancer diagnostics and treatment. Its portfolio includes specialized generators and kits that address unmet needs in oncology and cardiovascular disease.
Analysis
Management Discussion
The company demonstrated top-line growth with revenue rising from $11.2M in 2022 to $13.9M in 2024, driven by expanding demand for radiopharmaceuticals. However, profitability remains elusive as net income fluctuated between losses and breakeven, while operating expenses exceeded gross profit margins. Cash flow from operations turned positive at $638k, but significant cash outflows were required for investing activities totaling $685k.
Industry Overview
The global nuclear medicine market is expanding rapidly due to aging demographics and advancements in PET/CT imaging technologies. Companies producing short-lived isotopes are positioned to capture value as hospitals increasingly seek on-site production capabilities. Regulatory scrutiny remains high, but the demand for targeted cancer therapies continues to outpace supply growth.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $11.2M | $12.3M | $13.9M |
| Cost of Revenue | $4.9M | $4.9M | $5.3M |
| Gross Profit | $6.3M | $7.4M | $8.6M |
| Operating Expenses | $7.5M | $8.2M | $8.6M |
| Operating Income | $-1.2M | $-776.3K | $6.9K |
| R&D | $533.7K | $577.4K | $610.7K |
| G&A | $3.6M | $3.5M | $4.0M |
| Stock-Based Comp | $352.5K | $464.0K | $199.4K |
| D&A | $374.2K | $350.1K | $401.1K |
| Depreciation | $185.2K | $160.6K | $181.2K |
| Amortization | $164.4K | $164.9K | $164.9K |
| Other OpEx | $3.4M | $4.0M | $4.0M |
| Non-Operating Income | $0 | $0 | $0 |
| Interest Expense | $613.9K | $331.8K | — |
| Interest Income | $9.5K | $78.9K | $122.4K |
| Pre-Tax Income | $-1.2M | $-776.3K | $6.9K |
| Income Tax | $0 | $0 | $0 |
| Continuing Ops | $-1.2M | $-776.3K | $6.9K |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $303.2K | $-869.0K | $8.6K |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $303.2K | $-869.0K | $8.6K |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $5.7M | $5.8M | $5.0M |
| Cash & Equivalents | $2.4M | $2.7M | $1.9M |
| Accounts Receivable | $1.6M | $1.5M | $1.5M |
| Inventory | $744.8K | $927.1K | $820.9K |
| Prepaid Expenses | — | $672.9K | $698.0K |
| Other Current Assets | $1.0M | $0 | $0 |
| Long-Term Assets | $10.5M | $11.1M | $12.2M |
| PP&E (Net) | $2.0M | $2.5M | $3.3M |
| Goodwill | $1.4M | $1.4M | $1.4M |
| Operating Leases | $2.3M | $2.2M | $2.0M |
| Other LT Assets | $4.8M | $5.1M | $5.4M |
| Total Assets | $16.2M | $16.9M | $17.2M |
| Current Liabilities | $3.5M | $3.3M | $3.3M |
| Accounts Payable | $382.4K | $559.6K | $861.9K |
| Current Debt | $23.3K | — | — |
| Current Leases | $131.6K | $140.7K | $150.5K |
| Deferred Revenue | — | $932.7K | $513.3K |
| Other Current Liab | $1.5M | $158.6K | $308.4K |
| Long-Term Liabilities | $8.4M | $9.6M | $9.5M |
| LT Operating Leases | $2.2M | $2.1M | $1.9M |
| Other LT Liab | $6.2M | $7.5M | $7.5M |
| Total Liabilities | $11.9M | $12.9M | $12.8M |
| Shareholders' Equity | $4.3M | $4.0M | $4.3M |
| Paid-In Capital | $125.7M | $126.2M | $126.4M |
| Retained Earnings | $-126.5M | $-127.3M | $-127.3M |
| Total L&E | $16.2M | $16.9M | $17.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $303.2K | $-869.0K | $8.6K |
| Non-Cash Adjustments | $-1.9M | $717.0K | $1.5M |
| Working Capital Changes | $112.0K | $734.6K | $-907.4K |
| Cash from Operations | $-1.5M | $582.6K | $638.8K |
| Capital Expenditures | $120.0K | $149.1K | $721.2K |
| Cash from Investing | $3.9M | $-149.1K | $-685.2K |
| Cash from Financing | $-472.0K | $-80.5K | $-145.2K |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $1.9M | $353.0K | $-191.7K |
| Beginning Cash | $1.3M | $3.2M | $3.6M |
| Ending Cash | $3.2M | $3.6M | $3.4M |
Frequently Asked Questions
How does INTERNATIONAL ISOTOPES INC make money?
1) Short-Lived Isotope Production: Manufacturing high-activity isotopes like Gallium-68 and Copper-64 for PET scans. 2) Radiopharmaceutical Kits: Supplying ready-to-use kits for hospitals lacking on-site cyclotrons. 3) Custom R&D Solutions: Developing tailored isotope solutions for biotechnology partners and academic research institutions.
What are the main risks for INIS?
1) Regulatory Approval Delays: Stringent FDA and international regulations can slow product launches or halt existing operations. 2) Supply Chain Disruptions: Reliance on specialized target materials and reactor time creates vulnerability to upstream shortages. 3) Market Concentration: Heavy dependence on a few key partners and specific isotope types limits revenue diversification.
What is INIS's competitive advantage?
1) Specialized Production Capabilities: Proprietary technology enabling the production of short-lived isotopes that competitors cannot easily replicate. 2) Strategic Global Partnerships: Established distribution networks in key markets like the US and Japan ensuring consistent supply chains. 3) High Barriers to Entry: Significant regulatory hurdles and complex manufacturing requirements protect market share from new entrants.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.